Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692), a leading pharmaceutical company based in China, has announced a licensing agreement with domestic firm Biotheus. Under the terms of the agreement, Hansoh will secure exclusive global rights to develop, manufacture, and commercialize Biotheus’s bispecific antibody (BsAb) HS-20117/PM1080, along with sub-license rights. The agreement includes an upfront payment and potential commercial milestone payments that could total up to RMB 5 billion (USD 700 million), in addition to tiered royalties on global net sales.
HS-20117/PM1080, currently in the Phase I stage of development, is an EGFR/cMet BsAb with significant therapeutic potential. The drug is designed to block the signal transmission of both EGFR and c-Met, thereby inhibiting tumor growth and survival. This licensing agreement builds upon an initial deal struck in November 2022, which granted Hansoh exclusive rights to develop and commercialize the drug in Greater China, including Hong Kong, Macau, and Taiwan.- Flcube.com
